Biopharmaceutical company Dynavax Technologies Corporation (Nasdaq:DVAX) on Monday provided an update from Valneva SE's positive topline results from the Phase 3 pivotal trial of the inactivated COVID-19 vaccine candidate VLA2001 using Dynavax's CpG 1018 adjuvant.
The Cov-Compare (VLA2001-301) is a randomized, observer-blind, controlled, comparative immunogenicity trial in 4,012 adults and 660 adolescents. The trial is being conducted at 26 sites across the UK. About 2,972 participants 30 years of age and older were randomized in a 2:1 ratio to receive two intramuscular doses of either VLA2001 or AZD1222 at the recommended dose level, 28 days apart.
Additionally, CpG 1018 is the adjuvant used in HEPLISAV-B. Dynavax developed CpG 1018 adjuvant to provide an enhanced vaccine immune response, which has been demonstrated in HEPLISAV-B and in multiple COVID-19 vaccine candidates. CpG 1018 adjuvant provides well- developed technology and safety database, supporting development and large-scale manufacturing of a COVID-19 vaccine.
According to the company, VLA2001 successfully met both co-primary endpoints. Its superior neutralizing antibody titer levels were compared to active comparator vaccine, AstraZeneca's AZD1222 (ChAdOx1-S). Its neutralizing antibody seroconversion rate was above 95%. VLA2001 was well-tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients